Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.30 USD | +3.87% |
|
+3.43% | +2.15% |
Capitalization | 7.47B 7.22B 6.81B 6.01B 10.68B 648B 11.86B 81.11B 30.1B 269B 27.98B 27.43B 1,137B | P/E ratio 2024 * |
15.2x | P/E ratio 2025 * | 12.7x |
---|---|---|---|---|---|
Enterprise value | 10.91B 10.55B 9.96B 8.78B 15.61B 947B 17.33B 119B 43.98B 393B 40.89B 40.08B 1,661B | EV / Sales 2024 * |
2.7x | EV / Sales 2025 * | 2.21x |
Free-Float |
97.06% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Jazz Pharmaceuticals plc
1 day | +3.88% | ||
1 week | +3.43% | ||
Current month | +1.15% | ||
1 month | +2.14% | ||
3 months | -1.04% | ||
6 months | +16.30% | ||
Current year | +2.15% |







Director | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 61 | 24/10/2019 |
Philip Johnson
DFI | Director of Finance/CFO | 60 | 29/02/2024 |
Renée Galá
PSD | President | 53 | 30/09/2023 |
Manager | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CHM | Chairman | 61 | 24/10/2019 |
Seamus Mulligan
BRD | Director/Board Member | 64 | 17/01/2012 |
Rick Winningham
BRD | Director/Board Member | 65 | 31/12/2009 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 0 M€ | -.--% | - | |
14.47% | 248 M€ | -1.50% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+3.87% | +3.43% | +1.26% | -11.38% | 7.47B | ||
-0.16% | +5.06% | +17.72% | +268.15% | 782B | ||
-2.47% | +1.28% | -27.74% | +83.27% | 378B | ||
+1.13% | +1.73% | -1.08% | -6.89% | 371B | ||
+0.31% | +0.51% | +10.32% | +34.44% | 336B | ||
-0.83% | +0.77% | +26.68% | -17.36% | 256B | ||
-0.80% | +5.39% | +22.35% | +36.59% | 225B | ||
+1.13% | +2.56% | +11.82% | +22.90% | 210B | ||
+0.02% | +1.90% | +0.03% | +29.06% | 158B | ||
-1.26% | -1.18% | -7.57% | -49.66% | 147B | ||
Average | +0.11% | +2.19% | +5.38% | +38.91% | 287.18B | |
Weighted average by Cap. | -0.28% | +3.44% | +6.86% | +89.18% |
2024 * | 2025 * | |
---|---|---|
Net sales | 4.04B 3.9B 3.69B 3.25B 5.78B 351B 6.42B 43.89B 16.29B 146B 15.14B 14.84B 615B | 4.34B 4.19B 3.96B 3.49B 6.21B 377B 6.89B 47.14B 17.49B 156B 16.26B 15.94B 661B |
Net income | 519M 502M 474M 418M 743M 45.07B 825M 5.64B 2.09B 18.72B 1.95B 1.91B 79.08B | 603M 582M 550M 485M 862M 52.29B 957M 6.55B 2.43B 21.72B 2.26B 2.21B 91.75B |
Net Debt | 3.44B 3.33B 3.14B 2.77B 4.93B 299B 5.47B 37.41B 13.88B 124B 12.9B 12.65B 524B | 2.13B 2.06B 1.95B 1.72B 3.05B 185B 3.39B 23.18B 8.6B 76.92B 8B 7.84B 325B |
Date | Price | Change | Volume |
---|---|---|---|
11/02/25 | 126.76 $ | +2.63% | 172,933 |
10/02/25 | 123.51 $ | +2.68% | 856,837 |
07/02/25 | 120.29 $ | +0.18% | 615,903 |
06/02/25 | 120.07 $ | -1.20% | 461,720 |
05/02/25 | 121.53 $ | -0.08% | 499,838 |
Delayed Quote Nasdaq, February 11, 2025 at 05:43 pm
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAZZ Stock

MarketScreener is also available in this country: United States.
Switch edition